Clone: 4C5
Background: Lactoferrin (LF) is an iron-binding protein with bactericidal and bacteriostatic activity, which is stored within the secondary granules of granulocytes. LF expression is restricted to the post-mitotic maturation compartment of the granulocytic lineage, starting from the myelocyte stage. Normal and malignant myeloblasts are LF negative. The 4C5 antibody permits the identification and enumeration of human granulocytes using flow cytometry. Results must be put within the context of other diagnostic tests as well as the clinical history of the patient by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us.
Purification Method: Purified by Chromatography
Specificity: The LF mAb (clone 4C5) recognizes Lactoferrin stored within secondary granules of postmitotic granulocyte-committed cells. The sensitivity of 4C5 mAb is determined by staining well-defined blood samples from representative donors with serial-fold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity). For this purpose, a mAb concentration range is selected to include both the saturation point (i.e. the mAb dilution expected to bind all epitopes on the target cell) and the detection threshold (i.e. the mAb dilution expected to represent the least amount of mAb needed to detect an identical percentage of cells). In practice, 50 µl of leukocytes containing 10^7cells/ml are stained with 20 µl mAb of various dilutions to obtain a titration curve and to identify the saturation point and detection threshold. The final concentration of the product is then adjusted to be at least 3-fold above the detection threshold. In addition and to control lot-to-lot variation, the given lot is compared and adjusted to fluorescence standards with defined intensity.
Formulation: PBS pH 7.2, 1% BSA, 0.05% NaN3
References: 1. Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7. 2. Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21. 3. Cowland, J. B. & Borregaard, N. (1999) J Leukoc Biol 66, 989-954. Cramer, E., Pryzwansky, K. B., Villeval, J. L., Testa, U. & Breton-Gorius, J. (1985) Blood 65, 423-32.5. Groeneveld, K., te Marvelde, J. G., van den Beemd, M. WHooijkaas, H. & van Dongen, J. J. (1996) Leukemia 10, 1383-9. 6. Gullberg, U., Andersson, E., Garwicz, D., Lindmark, A. & Olsson, I. (1997) Eur J Haematol 58, 137-53. 7. He, J. & Furmanski, P. (1995) Nature 373, 721-48. Knapp, W., Majdic, O. & Strobl, H. (1993) Recent Results Cancer Res 131, 31-40. 9. Konikova, E., Glasova, M., Kusenda, J. & Babusikova, O. (1998) Neoplasma 45, 282-91. 10. Oehler, L., Majdic, O., Pickl, W. F., Stockl, J., Riedl, E., Drach, J., Rappersberger, K., Geissler, K. & Knapp, W. (1998) J Exp Med 187, 1019-28. 11. Paietta, E. (2003) Best Pract Res Clin Haematol 16, 671-83. 12. Rado, T. A., Bollekens, J., St Laurent, G., Parker, L. & Benz, E. J., Jr. (1984) Blood 64, 1103-9. 13. Rado, T. A., Wei, X. P. & Benz, E. J., Jr. (1987) Blood 70, 989-93. 14. Srivastava, C. H., Rado, T. A., Bauerle, D. & Broxmeyer, H. E. (1991) J Immunol 146, 1014-9. 15. Strobl, H. & Knapp, W. (2004) J Biol Regul Homeost Agents 18, 335-9. 16. Teng, C. T., Gladwell, W., Beard, C., Walmer, D., Teng, C. S. & Brenner, R. (2002) Mol Hum Reprod 8, 58-67.
UniProt: P02788
Caution: For professional users only. This reagent contains sodium azide. To avoid the development of hazardous conditions, reagents containing azide should be diluted in running water prior to be discarded. Similar to the work with other biological products, proper handling procedures are recommended.
English
Deutsch
